Field Medical, a clinical-stage company specializing in pulsed field ablation (PFA) technology, secured $35 million in Series B funding led by BioStar Capital and Cue Growth, with support from existing investors.
How the funding will be used: This financing will fund the pivotal VERITAS trial, development of the FieldForce Ablation System, and enhance Field Medical’s clinical and regulatory capabilities. Strong pilot data from the 2025 Heart Rhythm Society meeting contributed to this raise. Field Medical has now raised $75 million, reinforcing its leadership in PFA innovation for complex arrhythmias.
Board of directors changes: In alignment with its accelerated growth trajectory, Field Medical announced updates to its Board of Directors:
1.) Steven Mickelsen, MD, Founder and CEO, Field Medical – Electrophysiologist, serial entrepreneur, and inventor of pulsed field ablation technologies including FARAPULSE and FieldForce.
2.) Mark Wisniewski, CFO of Enterra Medical – Medtech operator with deep buy-side experience and M&A leadership, guiding Field through its next phase of value creation as chairperson of the Field Medical board.
3.) Marlou Janssen, Board Member at Field Medical, Sonion, Acarix, EBAMed, and Inspiration Healthcare – Experienced executive and board member, former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, bringing decades of commercial, product and clinical strategy leadership in cardiology and emerging medtech.
4.) Alexei Mlodinow, MD, MBA – Surgeon by training, serial entrepreneur, and investor with a track record in medtech innovation and multiple exits, including the $140 million acquisition of Surgical Innovation Associates.
5.) Ben Cannon, Founding Partner, Cue Growth – Seasoned VC investor with deep experience scaling growth-stage companies, offering institutional governance expertise and a performance-driven lens to support Field as the company scales.
KEY QUOTES:
“Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need. What is exciting is how VT is mirroring the early days of the AF market, strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.”
Steven Mickelsen, MD, founder and CEO of Field Medical
“Field Medical’s transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency. Their physician-led team brings the right insight, and their FieldForce platform brings the right tools. We’re proud to support this next chapter as they move closer to transforming VT care.”
Louis Cannon, MD, founder and senior managing director of BioStar Capital
“This round reflects the momentum building behind Field Medical, not only from our clinical results, but also from the strength of our business fundamentals. Our strong showing at HRS attracted institutional investor interest and reinforced continued support from existing investors, speaking volumes about the confidence in our technology, strategy, and leadership.”
Oskar Dadason, CFO of Field Medical
